Ongoing trials investigating ICIs in MPM (Source: Clinicaltrials.gov)

CombinationTreatmentIdentifier/referencePhaseSetting/line of treatmentStatusEstimated enrollmentNotes
VaccineNivolumab plus galinpepimut-SNCT04040231IReccurent/relapsedRecruiting10Open label, single group assignment
Single agentNivolumabNCT03063450 (CONFIRM)IIIRelapsedActive, not recruiting336Double-blind, placebo controlled
ICINivolumab plus ipilimumabNCT02899299 (CheckMate-743)IIIFirst LineActive, not recruiting606Open label, randomized
Nivolumab/nivolumab plus ipilimumabNCT02716272 (MAPS2)IIRelapsedActive, not recruiting125Open label, randomized
ChemotherapyDurvalumab plus chemotherapyNCT02899195 (PrE0505)IIFirst lineActive, not recruiting55Open label, non-randomized
Pembrolizumab/pembrolizumab plus chemotherapyNCT02784171II/IIIFirst lineActive, not recruiting520Open label, randomized
Nivolumab plus chemotherapyNCT04177953IIAdjuvantRecruiting92Open label, randomized
Atezolizumab plus gemcitabineNCT04480372IIRelapsedNot yet recruiting67Open label, single group assignment
Atezolizumab plus cisplatin and pemetrexedNCT03228537INeoadjuvantActive, not recruiting28Open label, single group assignment
RadiotherapyPembrolizumab after radiation therapyNCT02959463IMaintenanceRecruiting24Open label, non-randomized
Anti-angiogenicAtezolizumab plus bevacizumab and chemotherapyNCT03762018 (BEAT-meso)IIIFirst lineRecruiting320Open label, randomized
Photodynamic therapyNivolumab after intrapleural photodynamic therapyNCT04400539IIMaintenanceNot yet recruiting20Open label, single group assignment, pilot study